Evidence map›Paper›PMID 39745365›Full record

ArticleAntimicrobial agents and chemotherapy2025

Treatment with BKI-1748 after

Roberto Sánchez-Sánchez, Ana Huertas-López, Andrea Largo-de la Torre, Ignacio Ferre, Filippo Maria Dini, Michela Re, Javier Moreno-Gonzalo, Ryan Choi, Matthew A Hulverson, Kayode K Ojo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Roberto Sánchez-SánchezSALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Community of Madrid, Spain.ORCID 0000-0002-5067-2636
Ana Huertas-LópezSALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Community of Madrid, Spain.
Andrea Largo-de la TorreSALUVET-Innova S.L., Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Community of Madrid, Spain.
Ignacio FerreSALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Community of Madrid, Spain.
Filippo Maria DiniDepartment of Veterinary Medical Sciences, University of Bologna, Bologna, Emilia-Romagna, Italy.
Michela ReSALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Community of Madrid, Spain.
Javier Moreno-GonzaloSALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Community of Madrid, Spain.
Ryan ChoiCenter for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Matthew A HulversonCenter for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-3413-4969
Kayode K OjoCenter for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Samuel L M ArnoldDepartment of Pharmaceutics, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-8290-2347
Andrew HemphillInstitute of Parasitology, Vetsuisse Faculty, University of Berne, Berne, Switzerland.
Wesley C Van VoorhisCenter for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Luis Miguel Ortega-MoraSALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Community of Madrid, Spain.ORCID 0000-0002-4986-6783

Funding

Bumped-Kinase Inhibitor Drug Development for ToxoplasmosisR01HD102487 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$3.3M
HHS | National Institutes of Health (NIH) grant R01 HD102487NICHD NIH HHS R01 HD102487Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) grant No. 310030_214897U.S. Department of Agriculture (USDA) grant 2020-67015-30881
6 · The paper itself

Abstract

Drug development for congenital toxoplasmosis is challenging since first-line therapy has a high rate of adverse effects and exhibits suboptimal efficacy. Bumped kinase inhibitors (BKIs), targeting protein kinases with small gatekeeper residues, have been found to be effective against

Indexed as

Antiprotozoal AgentsProtein Kinase InhibitorsSheep DiseasesToxoplasmaToxoplasmosis, AnimalToxoplasmosis, CongenitalAnimalsFemaleFetusPregnancySheepAntiprotozoal AgentsProtein Kinase InhibitorsBKI-1748, treatmentcongenital toxoplasmosissheepToxoplasma gondii

Identifiers

PMID39745365
PMCPMC11823607

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.